Table 1– Characteristics of multidrug-resistant tuberculosis (MDR-TB) patients with different resistance patterns of Mycobacterium tuberculosis
MDR-TB onlyMDR-TB+INJrMDR-TB+FQrXDR-TBTotal MDR-TB cases
Studies n2622181726
Cases n476311304264056724
Demographic characteristics
 Age years39.2±13.539.9±13.341.6±14.340.6±13.839.5±13.5
  Male6874686769
 HIV-infected145.11.73.711
Clinical characteristics
 Pulmonary TB only9797969797
 Sputum-smear positive7373797974
 Cavities on chest radiography6566607766
 Extensive disease#7271787873
 Previous TB treatment
  None2024191630
  First-line drugs only7360645760
  Second-line drugs for MDR-TB716172710
 Had a serious adverse event during therapy2947334332
  • Data are presented as mean±sd or %, unless otherwise stated. Values shown were computed using simple pooling across all studies. Percentages were calculated on the number of patients in each group with information available. MDR-TB: multidrug-resistant TB (resistance to at least isoniazid and rifampicin); MDR-TB only: MDR-TB, but susceptible to fluoroquinolones, amikacin/kanamycin and capreomycin (at least one second-line injectable drug tested); MDR-TB+INJr: MDR-TB plus resistance to amikacin/kanamycin and/or capreomycin, but susceptible to fluoroquinolones; MDR-TB+FQr: MDR-TB plus resistance to any fluoroquinolone, but susceptible to amikacin/kanamycin and/or capreomycin (at least one second-line injectable drug tested); XDR-TB: extensively drug-resistant tuberculosis (MDR-TB plus resistance to any fluoroquinolone and any second-line injectable drug (amikacin/kanamycin and/or capreomycin)). #: Extensive disease was defined as sputum-smear positive, or cavities on chest radiography if information about sputum-smear was missing. : Previous tuberculosis (TB) treatment was defined as treatment with any TB drug for ≥=1 month. Previous treatment could be with first-line drugs or with ≥2 second-line drugs for MDR. In some patients, information was only available that they had been treated previously for TB, but not whether this was with first- or second-line drugs.